论文部分内容阅读
目的:通过检测系统性红斑狼疮(SLE)患者血清补体因子H(CFH)的表达水平,探讨其水平变化与SLE患者其他实验室检测指标关系及其在SLE发病中的作用。方法:选取符合1982年美国风湿病学会制定的SLE诊断标准的37例SLE患者,另选30例健康对照者,采取酶联免疫吸附法(ELISA)检测SLE组及对照组血清中的CFH的水平,同时检测临床相关指标,分析CFH在各组患者血中的变化及其与临床各指标的相关性。结果:SLE患者血清CFH水平为(332.96±135.27)μg/L,低于正常对照组水平[(414.81±72.79)μg/L,P<0.05]。SLE血清CFH水平与补体C3呈明显正相关(r=0.518,P<0.001),与ds-DNA,尿微量白蛋白,SLEDAI评分呈负相关(r=-0.425,P<0.05;r=-0.472,P<0.05;r=-0.369,P<0.05)。结论:CFH的减少可能参与SLE的发病过程,特别与SLE造成肾脏损伤有关,是导致SLE患者低补体血症的因素之一,在一定程度上可反映疾病活动程度。
Objective: To investigate the relationship between serum levels of complement factor H (CFH) and other laboratory markers in patients with systemic lupus erythematosus (SLE) and its role in the pathogenesis of SLE. Methods: Thirty-seven patients with SLE who were selected according to SLE diagnostic criteria established by the American College of Rheumatology in 1982 were selected and 30 healthy controls were selected. Serum levels of CFH in SLE group and control group were detected by enzyme-linked immunosorbent assay (ELISA) At the same time, the clinical related indexes were tested, the changes of CFH in each group of patients’ blood and the correlation with CFH were analyzed. Results: The level of serum CFH in SLE patients was (332.96 ± 135.27) μg / L, which was lower than that of the control group [(414.81 ± 72.79) μg / L, P <0.05]. The level of serum CFH in SLE was positively correlated with complement C3 (r = 0.518, P <0.001), and negatively correlated with ds-DNA, urine microalbumin and SLEDAI scores (r = -0.425, , P <0.05; r = -0.369, P <0.05). CONCLUSION: The decrease of CFH may be involved in the pathogenesis of SLE, especially related to kidney damage caused by SLE. It is one of the factors leading to hypocomplementemia in patients with SLE and may reflect the degree of disease activity to a certain extent.